Satish Reddy is the Chairman of Dr. Reddy's Laboratories. He joined the company in 1993 as Executive Director and since then has held positions of increasing responsibility as Managing Director in 1997 and Vice-Chairman & Managing Director in 2013. Satish led the organisation's transition from a unifocused manufacturer of APIs (active pharmaceutical ingredients) to a company that moved up the value-chain with a diverse product portfolio of Finished Dosage Formulations. He oversaw the expansion and establishing of a strong footprint for Dr. Reddy's nished dosage products in Russia, CIS countries and other emerging markets.
As an active member of major industry associations and governmental panels, Satish played a key role in shaping policies concerning the pharmaceutical sector as well as the economy, such as policy formulation on India's patent law, drug pricing and important amendments to the Drugs & Cosmetics Act. He was a member of the Drugs Technical Advisory Board of India, the Chairman of the Andhra Pradesh Chapter of the Confederation of Indian Industries (CII) and head of its National Committee on Pharmaceuticals. He was the President of the Indian Pharmaceutical Alliance, a premier industry association of leading research based Indian companies. Satish also Chairs the Life Sciences Skill Development Council under The National Skill Development Corporation (NSDC), an organization, working in partnership with various stakeholders groups, to serve and address the skill shortfalls in the Life Sciences Sector across India. In May 2015, the Ministry of Labour and Employment, Government of India, nominated Satish as Chairman of the Board of Governors of the National Safety Council.
Keeping true to the legacy of the founder of the company, Dr. Anji Reddy, Satish drives the organisation's Corporate Social Responsibility initiatives. The Dr. Reddy's Foundation, of which he is Chairman, works to help the less privileged create sustainable livelihoods through appropriate vocational education. He is a Trustee of the Naandi Foundation, which works in the areas of child rights and education, safe drinking water, agriculture export marketing support and other much needed empowerment initiatives that India needs. Satish is also one of the Directors of Dr. Reddy's Institute of Life Sciences, the not- for-prot institute engaged in pioneering and innovative research in unifying areas of chemistry, biology and chemical biology.
Satish was identied as a "Young Global Leader for 2007" by the World Economic Forum, and was presented with the "IBLA - India Corporate Citizen of the Year" award by CNBC in 2005 for his contributions to Corporate Social Responsibility. He holds a degree in Chemical Engineering from Osmania University, India, and an M.S. in Medicinal Chemistry from Purdue University, USA, where he received the 2009 Distinguished Alumnus Award from the School of Pharmacy and Pharmaceutical Sciences.
Head of the Division for EU and International Affairs, Ministry of Health and Social Affairs, Government of Sweden
Niclas Jacobson, born 1966. Bachelor in Political Science, Uppsala University, Has since 1992 held different positions within the Swedish Government Offices, e.g. Ministry for Foreign Affairs and Ministry of Health and Social Affairs. Between 2004 and 2010 he worked specifically with issues related to ageing and elderly care. In 2008 he was appointed Administrative Head of the special commission to draft minimum standards of competence to work within elderly care. Since 2011 he is Deputy Director- General and Head of the Division for EU and International Affairs within the Ministry of Health and Social Affairs. Between 2011-2014 chairman of the EU Social Protection Committee Working Group on Ageing (SPC-WG-AGE). Mr Jacobson has been co-charing the Joint Working Group overseeing the MoU in Health between India and Sweden since 2011.
Sudarshan has a strong passion for healthcare and the education sector. He is currently the Secretary General of Indian Pharmaceutical Alliance (IPA), Senior Advisor with APAX Partners and is also a Board member of multiple organizations. He has served in several leadership positions over the years and was earlier the Managing Director at Abbott Healthcare Solutions.
Sudarshan has a rich healthcare business experience of over 40 years which includes stints in Abbott, Johnson & Johnson and leading Indian companies. He has got extensive experience in field force management, brand building and overall business operations in healthcare companies. He has been associated with over 30 brands which are among the top 300 in the Indian Pharmaceutical industry. His experience covers Pharmaceutical, OTC, Hospital, Diagnostic & Nutrition business. He has received number of recognitions for his contributions within the company, with academic institutions and with industry associations. He is the first Indian recipient of the Global Chairman’s Award at Abbott.
Sudarshan has also served as Vice President of Organization of Pharmaceuticals Producers of India (OPPI) representing research based pharmaceutical companies. He is currently the member of the Board of Abbott India, Healthium Limited (APAX portfolio company), Zandu Chemicals Limited, PharmEasy, Indian Institute of Health Management Research, Jaipur, member of the Advisory Board of Narsee Monjee University, Mumbai (NMIMS), Board Member of Indian Education Society (IES) and Charter Member of The Indus Entrepreneurs, Mumbai (TiE). He is a Certified Executive Coach from Coaching Foundation of India. He has also contributed in shaping the healthcare policy and improving access to healthcare in India.
Sudarshan is an alumni of St. Stephens College, Delhi and Indian Institute of Management, Ahmedabad.
Manni Kantipudi is the Director & Chief Executive Officer of GVK BIO. He joined GVK BIO in 2007 as President and has steered the company’s direction and growth to be one of Asia’s leading life sciences solutions organization.
Manni is also a Director and Chairperson on the Board of Aragen Bioscience Inc, a fully owned subsidiary of GVK BIO, based in Morgan Hill, California. Aragen Bioscience is focused on large molecule R&D solutions.
Prior to joining GVK BIO, Manni was in the IT industry, where he spent 16 years with Intel, holding various leadership positions in the USA and Asia. At Intel Manni held Senior leadership roles. He served as the Head of Intel India, the CIO of Intel for Asia and was responsible for the software in Intel’s Wi-Fi product line Centrino.
Manni holds a Master of Science Degree in Computer Science from Arizona State University and a BE in Computer Engineering from Bombay University. He completed all his Ph.D. requirements and joined Intel prior to completing his dissertation.
Dr Gaurav Laroia is a Senior Vice President at Biocon Biologics. He is entrepreneurial leader with 20 years of strategic, operational and management consulting experience in the Healthcare Industry in developed and emerging markets. Gaurav is passionate about providing better healthcare for patients. He has a deep understanding of the pharmaceutical value chain with experiences across P&L, global marketing, business development, alliance and project management and R&D having worked in roles of increasing responsibility at McKinsey, Sanofi, Merck & Co, and Roche. He has been recognized for spotting and seeding innovation across organizations has been a recipient of the Golden Peacock, Mathan and CII Innovation Awards. Gaurav is a PhD in Molecular & Cellular Biology from New York University and a MS in Genetics from the University of Cambridge UK where he was a Commonwealth Trust Scholar. He is published in scientific and management journals such as Science, Research and Technology Management, etc. Prior to joining Biocon Biologics, Gaurav was the General Manager for Roche Diabetes Care in India.
Dr. K.Anand Kumar has a Ph.D in Microbiology from Indian Council of Medical Research (ICMR) and has over 25 years of experience in the biotechnology/pharma Industry.
Dr. Kumar is currently the Managing Director at Indian Immunologicals Ltd (IIL). Indian Immunologicals Ltd, a subsidiary company of National Dairy Development Board (NDDB). He is a whole time Director on the board of IIL and is also a director at its subsidiary Pristine Biologicals NZ Ltd.
Prior to IIL, Dr.Kumar worked as Associate Vice President – biotech operations at Wockhardt Ltd.
He has worked for more than a decade outside India for companies such as Pfizer Global Manufacturing in Australia and Schering Plough Animal Health in New Zealand.
Dr.Kumar is a member of the National Biotechnology Expert Committee with FICCI and CII. He was an executive committee member of Parenteral Drug Association (PDA), Australia and currently is on the expert panel on analytical methods related to vaccines with the Indian Pharmacopeia (IP). He served as an expert volunteer with United States Pharmacopeia (USP) during the period 2010-15. He has been a speaker at various international forums.
Dr.Kumar undertook Senior Management Development Programme at the Indian Institute of Management, Ahmedabad.
He has vast experience in various fields related to the biotech/vaccine Industry including Strategy, Business Development, Manufacturing Operations, Commercialization of products, R&D, Quality, Project Management etc.
He has actively contributed to the commercialization of various products in the vaccines and biotech space.
He is listed in the top 40 influencers in the Indian biopharmaceutical industry by Terrapin, a leading consultancy firm from Singapore in 2013.
Jean Pierre’s career has taken him across the globe, having worked across, Americas, Europe, Africa and more recently in Asia. He has rich marketing and management experience in the healthcare industry and is passionate about public health.
He has worked on the introduction of pertussis and polio vaccines in national immunization programs, and has led important public private partnerships aiming at increasing access to immunization. He has also played a pivotal role in bringing innovative vaccines to developing nations.
Jean Pierre has moved progressively across roles from finance, driving strategic planning, running global operations and shaping growth initiatives in developed and emerging markets. He has transformed and built top performing teams across geographies by creating an ecosystem to nurture an entrepreneurial mindset.
He started his career with Sanofi (erstwhile Aventis), where he held several roles of increasing responsibilities in Europe and emerging markets. Jean-Pierre has also served as the Attaché to the President and CEO of Sanofi Pasteur, based in the USA.
He has a Master’s degree in Economics from Ecole Superieure de Commerce de Compiegne in France and also attended the Marketing programs of University of Pennsylvania - The Wharton School, USA and INSEAD, France.
An avid runner, Jean Pierre lives in Mumbai, India with his wife and kids.
Dr Rahul Purwar is an Associate Professor at Department of Biosciences & Bioengineering at IIT Bombay and founder of ImmunoACT Pvt Ltd (Immunoadoptive Cell Therapy Private Limited), Mumbai. The ImmunoACT and Prof. Purwar developed indigenous platform of CAR-T cell technology for cancer treatment and are committed to bring CAR-T cell therapy to Indian patients at affordable cost. He holds a PhD degree in Molecular Medicine from Hannover Medical School, Germany and has completed his Post-Doctoral training from Harvard Medical School, Boston, USA. He has worked as a Scientist at the Department of Translational Medicine, ImmunoGen, Inc., an Oncology company at Waltham, MA, USA. His research work is published in highly prestigious journals like Nature Medicine, Journal of Immunology etc. He has been awarded with several awards, one of which is the Melissa K. Bambino Memorial Award by The Skin Cancer Foundation, USA. His main area of research is T cell biology focussing on cancer immunotherapy as well as inflammation.
Pushpa leads the healthcare and lifesciences practice of Sathguru, a 30 year old consulting firm known for its expertise across strategy, corporate finance and innovation advisory.
Pushpa has led in the pharma and biotech segment include segment strategies for leading pharma companies for biosimilars and peptides segments, pharma focused mid-term investment strategy for global PE fund with more than $1.5billion AUM in India, human vaccines segment strategy for a biotech company, policy advisory on preparedness for adoption of identified public health priorities and licensing transactions for phase III monoclonal antibodies for US market, microsphere drug delivery platform for peptide formulation and several 505(b) (2) assets.
Pushpa’s prior experience of about fourteen years includes leading consulting engagements in PwC and E&Y and technology transfer experience at the University of Michigan Technology Transfer Office. She has a bachelor’s degree from Osmania University (India), an MBA from the Ross School of Business at University of Michigan and is a member of the Institute of Chartered Accountants of India.
Vikas Dandekar works for ET Prime, a highly rated paywalled website from The Economic Times for deep-dive analysis and insights for discerning business readers. For over two decades, Vikas has reported on the pharmaceutical industry, holding various positions in The Indian Express Group, CNBC, Elsevier Business Intelligence and now with The Economic Times. He dreams to see a globally-recognized, fully invented and developed medicine from an Indian drugmaker.
He is a graduate in Commerce and a qualified cost accountant.
He is a second generation entrepreneur, who has steered his organization towards becoming a trusted supplier of Active Pharmaceutical Ingredients and intermediates for pharmaceutical formulation companies in India and abroad. Synthokem Labs has USFDA approved facilities. Other certifications include Certificate of Suitability, Written Confirmation, WHO GMP Certificate, Kosher Certification, Cofepris and ISO 9001-2008.
Mr. Jayant Tagore is an active member in the industry bodies. He has served as the president of Bulk Drug Manufacturers Association (India). He is one of the founder executive committee members, and has also served as the Secretary for the association during the period 2004-06.
Mr. Jayant Tagore is the Executive Committee member of Pharmaceuticals Export Promotion Council of India (PHARMEXCIL) since inception.
He has been awarded by the state and central governments for his initiatives in harnessing solar energy for industrial purposes.
Mr. Jayant Tagore is a committee member of Sharada Vidyalaya Institutions, which have been running a School, Junior college and Degree & PG College for the under-privileged girl students in the old city of Hyderabad for the past 80 years.
He also contributes to charity initiatives towards child health and education. He is the managing trustee for Balakrishna Rao Charitable Trust which supports more than 200 students financially every year.
He is an active sports person who golfs and travels extensively on work and leisure.
Sunil is a Managing Director with Quadria Capital, an Asian healthcare focused private equity fund with managed assets of over US$1.8 billion
Sunil has an extensive healthcare investment and transaction experience across the Asia-Pacific market and has been involved in some of the landmark deals in the healthcare space
In his career spanning 18+ years, Sunil has led and executed deals worth over US$ 7 billion across M&A and Capital Raise.
Sunil serves on the board and committees of various healthcare companies and few prestigious institutions.
Sunil is a and governing council member of NATHEALTH and a member on CII – National Committee on Biotechnology
Prior to Quadria Capital, Sunil has worked with Religare Capital Markets and PNB Gilts at various senior positions.
He has a Masters Degree in International Business from Delhi School of Economics
As Head – Strategic Partnerships & Entrepreneurship Development at BIRAC is excited to nurture and empower the Biotech Innovation Ecosystem in India. At national level facilitates drivers for enabling and supporting startups, capacity building through bioincubators, creating investment opportunities through Angel & VC funding, cofunding, scaling, global integration of ecosystem through a strategic network of national and international partnerships. Promotes BIRAC’s mandate to support translation of innovative ideas to PoC, validation to commercialization for globally competitive affordable products and technologies to address unmet needs in Health care, Diagnostics, Medical Devices, Industrial biotech, Agriculture, secondary Agriculture, Waste management, Clean Energy and related areas.
He has about 25 years of global Industry & Academia R&D experience in Pharma/ Biotech sector from discovery research to product development, Leadership, Project Management and Administration. Contributed to Clinical Drug Candidates for global drug development at Daiichi Sankyo (India), Daiichi Sankyo (Japan), Ranbaxy, Dabur and University of Alberta (Canada). Developed certain technologies that were transferred from academia during doctoral (ICGEB, NII) and post-doctoral research (KAIST South Korea; University of Alberta) to industry. Trained in Pharmaceutics, Molecular Pharmacology, Immunology with hands-on in FIC and BIC Drug Discovery, Translational Preclinical Research and Early Clinical Development in therapeutic areas of Chronic Inflammation, Oncology, Infectious diseases, Autoimmune disorders and drug delivery. He serves on several national level committees and advisory boards, and contributes in national and international forums
Over 39 years of experience in Global Pharmaceutical MNCs as a Successful Manager in various roles - General Management ( Overall Management of the Company ) , Marketing & Sales roles & Excelling in diverse multicultural environments . A strong proponent for Building Big Brands & enhancing Corporate Equity through Patient & Customer Focus . Launched & Built Brands in Multiple Therapeutic segments , & managed overall P&L of Business Units . Actively involved in Mergers, Acquisitions & Integrations , Change Management process without losing sight of Performance . Developed Human Capital through continuous Training & Development programs. Encourage Innovation & promote / create Healthy Competitive working environment . Have always created a working environment of Trust , Fairness ,Openness , Integrity & Compliance .
Was associated with Anderson Consulting for Business Process Re Engineering project . Have attended various Marketing & General Management programmes in reputed institutes like INSEAD ( Singapore ) , IIM Ahmedabad , Bangalore & ASCI Hyderabad .
Joy Chakraborty is currently holding the position of Chief Operating Officer at P.D.Hinduja Hospital & Medical Research Centre. He joined P.D. Hinduja Hospital in March, 2007 as Dy. Director - Administration. He is overall responsible for operations and implementation of business strategies of the hospital. He also manages logistics and marketing function of the hospital. He is passionate in nurturing new ideas and thoughts for experiments in the process of healthcare delivery. His current responsibility is to ensure optimal level capacity utilization of hospital resources. He is also keen in developing knowledge management in healthcare along with creating trained human resource pool for the sector especially for the segment of allied health professionals.
Prior to joining Hinduja Hospital he has had 9 years of experience in working for Sri Ramachandra Medical Centre (SRMC), Chennai associated with Sri Ramachandra Medical College (Deemed University). As an administrator he managed the entire operations and administration function of the hospital as a leader and member of a large team. He was instrumental in starting MBA Program in Hospital and Health Systems Management in Sri Ramachandra University. He worked there as Honorary Asst Professor. He was a visiting faculty for the College of Nursing for B.Sc and M.Sc program; College of Allied Health Sciences and College of Physiotherapy in the same University. Joy was also a visiting faculty in Loyola Institution of Business Administration (LIBA), Apollo Institute of Hospital Administration, Chennai for Healthcare Management Courses on regular basis. He visits IIHMR to deliver guest lectures. WHO nominated international students have undergone Hospital Managements internship under him.
Before starting his career, he completed his Post Graduation in Healthcare Management and subsequently P G diploma in Marketing & Sales Management after obtaining basic degree in Human Physiology from Kolkata University. Subsequently he has attended advanced management program in Finance (Finance for Business Leaders) from IIM, Ahmedabad. He has undergone advanced Executive Education from Harvard Business School in Managing Healthcare Delivery.
Joy is currently, Chairman- Healthcare Initiatives of CII (Western Region), President – Voice of Healthcare (Western India), Member of National Healthcare Committee of CII; Secretary of Association of Healthcare Providers of India (AHPI - Maharashtra & Goa); Member of Advisory Board of Healthcare Programs (IIM-Calcutta); Member of Industry Academia Board (XLRI – Jamshedpur). He is also a Member of the Accreditation Committee of NABH and Health Sector Skill Council (HSSC) ); Advisory Board Member – National Educational Policy, Medical Education, Ministry of HRD, Govt. of India. Additionally he is a member of prestigious bodies like American Society for Quality (ASQ) and Academy of Hospital Administrators. He has been invited in the board of studies and many other positions in various academic institutions across the country. He has also worked very closely with Harvard Medical International for the improvement of healthcare outcome.
Joy has been invited by Govt of Maharashtra in the Committee of Developing state’s Clinical Establishment Act (CEA) as a Member.
Joy is currently Member of Harvard Business Review Advisory Council.
Joy has been awarded Rashtriya Sanman Award by National Education & Human Resource Development Organization.
Akansh is the founder and CEO of THB. He is passionate about data-backed value creation and believes that healthcare industry offers the most exciting opportunities of leveraging data for a holistic impact. Akansh is a computer science engineer, and an MBA from London Business School. He has had 10+ years of experience with Bain & Company, a management consulting firm, and in private equity with Abraaj Capital, Helion Ventures, and Ennismore Capital.
Parijat Ghosh is a partner in Bain & Company and based in the New Delhi office. An expert in healthcare and the Advanced Manufacturing & Services practices, Parijat leads the firm's Asia Pacific Results Delivery® practice. He has almost 20 years of management consulting experience across India, the United States and Europe.
Parijat advises clients across a number of sectors within the healthcare industry, including payers and services, hospitals, pharmaceuticals and biotechnology.
He holds deep expertise in growth strategy, sales and marketing, innovation, organization design, executive development and strategy implementation. He also has substantial industry experience in automotive and building products. Prior to joining Bain, Parijat was a leader at two other global consulting firms.
A regular contributor of insights to think tanks, Parijat is a member of the CII National Committee on Pharmaceuticals as well FICCI’s Healthcare Committee. Recently, he led a Bain & Company report on Operational excellence in healthcare with Nathealth, and has been a consistent speaker at CII’s pharma events over the past few years. His opinions and quotes on the sector can be found in media across leading business dailies including the Economic Times, Times Of India, Mint and such others. Besides, steering the practice he also serves as the head and vice president of human resources at Bain India.
Parijat earned an MBA from IIM Ahmedabad and holds a graduate degree in B. Tech (Honors) in Manufacturing Science and Engineering from the Indian Institute Technology, Kharagpur.
Ms. Samina Vaziralli is the Executive Vice-Chairperson of the Company, and represents the third generation of Cipla’s founding family. Samina is a MSc in International Accounting and Finance from the London School of Economics and Political Science. An alumna of the London School of Economics, she has in the past worked in UK and the US with the leading global firm Goldman Sachs before joining the Cipla leadership team in 2011.
Samina joined Cipla in the year 2011 as a member of management team. In the year 2013, she was designated as the “Head Strategic Projects – Cipla New Ventures”. She was appointed as an Executive Director of the Company w.e.f. 10th July, 2015 and subsequently she was elevated as the Executive Vice-Chairperson of the Company, w.e.f. 1st September, 2016. She has been instrumental in driving the Company’s current transformation agenda. Samina played a key role in successfully incubating and shaping Cipla Health Limited, spearheaded Cipla’s ambitious foray into the US market with strategic acquisitions. Samina has built a top-class leadership pipeline for the Company as it continues to spread its wings globally.
As Executive Vice-Chairperson of Cipla, Samina focuses on board and governance issues, in addition to furthering Cipla’s strategic priorities through key global partnerships, corporate culture, hiring the right talent, and public advocacy. Recognised as the promoter face of Cipla, Samina has been feted for her diverse work experience and business knowledge. In 2017, she received the ‘Most Powerful Women in Business’ award from Business Today. In 2018, Forbes named Samina among the top 25 emergent women business leaders in Asia, and Fortune India named her among the most powerful women in business.
Sharad Tyagi has almost three decades of experience that spans across pharmaceuticals, personal care, automotive , environmental engineering, textiles & chemical industries. He has expertise in creating organizations and businesses from start-up and has extensive global business experience including Middle east, Asia, Europe and U.S.
After an engineering degree from Delhi University, Sharad completed his PGDM from the Indian Institute of Management (IIM), Ahmedabad in 1985 and began his career with ICI. After successfully setting up the Personal Care business in the Specialty Chemicals division of ICI, he joined Engelhard Corporation in 1996 as the Country Manager for India and Head of Strategy for Asia, positions he held for ten years. During this period, he was instrumental in setting up one of the earliest catalytic converters’ operations and businesses in India and China for Engelhard. His last assignment was with Dr Reddy’s Labs Ltd, where he was the Head of Marketing and Sales for the global API business.
For the past 9 years, Sharad has been executing Boehringer Ingelheim‘s high-growth strategy for Human Pharma India, which involves launch of new innovation brands, synergising the Boehringer Ingelheim – Lupin alliance for diabetes and launch of Animal Health Business.
Dr. Yasir Rawjee joined Glenmark Life Sciences in May 2019, to lead the company as Chief Executive Officer. Yasir began his career in Chemical Development with SmithKline Beecham Pharmaceuticals and GlaxoSmithKline in the USA where he worked for a period of nine years. He then moved back to India and joined Matrix Laboratories in 2004 where he setup the Contract Manufacturing business. After the merger of Matrix with Mylan, he was responsible for the Sales and Marketing function for the API Business, as Senior VP and Head in Mylan for a period of 4.5 years. Since 2012, he moved into API Operations where he held positions of increasing responsibility at Mylan including Senior Vice President of API Technical Operations and Senior Vice President & Head of Global API Operations at Mylan. Yasir earned his Ph.D. degree in Chemistry from Texas A&M University in the USA, a B.Sc.(Tech.) from UDCT, India and a B.Sc (Honours) from St. Xavier’s College, Mumbai.
Bharat Reddy is the Executive Director of the MSN Group of companies. An accomplished technocrat with an experience of over 20 years, Bharat has displayed his adeptness in handling profiles including information technology, life science and pharmaceuticals.
Bharat holds an exemplary academic record with a Master’s degree in Business Administration from the University of Florida, Masters in Computer Science from FloridaAtlanticUniversityandathirdMastersfromClemsonUniversity.
As an Executive Director,Bharat plays a significant role in MSN’s global pharmaceutical operations, sales and marketing. His expertise in developing market-specific business strategies coupled with strong emphasis on creating brand identity, has helped MSN Groupmarkitspresenceworldwide.
Overseeing the overall business development of MSN group, Bharat leads the operations of the formulation business, Information Technology and new avenues for MSN group worldwide
Satyam Mehra is a partner in Bain & Company's New Delhi office. He is a leader in Bain India's Healthcare practice and a member of the firm's Financial Services and Private Equity practices.
He has nearly 15 years of experience in North America and India, with more than 10 years in consulting with Bain.
Satyam joined Bain's Boston office in 2005 and has advised major clients across a range of Consumer Services verticals, including Healthcare Delivery, Pharma and Financial Services.
Within Financial Services, Satyam has worked on assignments with NBFCs, Housing Finance Cos, and players in the Payments space. In addition, he has led numerous projects in the Private Equity ring-fence and has extensive experience advising clients on Customer Strategy and Commercial Due Diligence. His recent assignments include devising the growth strategy for a Payments player, re-organization in a leading NBFC and the turnaround strategy for a Healthcare Delivery leader.
Satyam contributed to Bain's Aarogya Bharat: India Healthcare Roadmap for 2025 report. He has also been published and quoted in leading business dailies and recently he also addressed a panel at the Business World Summit and Awards on private equity investments in hospitals.
Satyam holds an MBA from IIM Ahmedabad and is a qualified Chartered Accountant.
Mukesh is currently working as the Chief Information Officer for Dr. Reddy’s Laboratories Ltd. He has global responsibility for Digital Transformation, Process Excellence and Information Technology Management for the organization.
He has more than 20 years of experience doing various roles across industries – Business Process Consulting, Supply Chain Advisory, Digital Strategy and execution.
He has worked across FMCG, Automotive, IT and Pharma Industries. He is a Industrial Engineer from IIT Kharagpur and MBA from IIM Lucknow.
Kedar Upadhye has been Joint President and Global Chief Financial Officer of Cipla since August 2016, heading its Global Finance and Information Technology functions. Prior to joining Cipla, Kedar was Vice President, Finance, and Head of Investor Relations at Dr. Reddy’s Laboratories. He has previously worked with Pepsi India and the Thermax Group. Kedar is a qualified Cost Accountant and Company Secretary, and an alumnus of the Indian Institute of Management, Bangalore.
Kedar is a dynamic people leader with strong domain expertise and thorough understanding of the global pharmaceutical industry. At Cipla, Kedar provides leadership and strategic oversight to multi-locational finance teams operating throughout the globe. He has spearheaded several high-impact organisation-wide projects and practices to enable strategic business partnering, drive efficiencies, cost improvements, analytics, automation, and best practice in governance. Kedar has played a key role in the improvement in the operating margin and profitability of the company in the last three years.
As a member of the Management Council of Cipla, Kedar is an integral part of decisions on identifying levers of growth, strategic acquisitions and divestments, and cost optimisation projects.
In 2018, Kedar was awarded the IMA India CFO Award for Excellence in Cost Management in recognition of the significant improvements and sustainability of practices made in Supply Chain, Operations, General & Administrative spends and various other workstreams. Under his leadership, the Company has been recognised for strengthening its governance practices through the Golden Peacock Award for Excellence in Corporate Governance 2018 by the Institute of Directors, India; the 18th ICSI National Award for Excellence in Corporate Governance from the Institute of Company Secretaries of India; and ranked second for voluntary disclosures on the India Disclosure Index 2018 by FTI Consultants.
Dr. Azadar Khan currently heads India Regulatory Affairs, Corporate Relations, and Corporate Social Responsibility at Sun Pharmaceutical Industries Limited. He is an Industry veteran, carries over 38 years of rich experience in Pharmaceutical Industry encompassing domain of Regulatory Affairs, Corporate Relations, Corporate Social Responsibility and Human Resources. He has represented Sun Pharmaceutical Industries Ltd., as well as Indian Pharmaceutical Industries at various forums of the policy makers/stakeholders and provided advisory for overall growth of the industry. He has been conferred Honorary Doctoral Awards (Honoris Causa) in the field of Management, by the Governing Council of Confederation of International Accreditation Commission in affiliation with KEISIE International University-KIU, South Korea.
Chandrima Sinha joined Invest India as Vice President in February 2016, where she set up and helped built over 30 sectoral teams. Currently, she leads the multi-stakeholder initiative, India Investment Grid (IIG), which promotes India as an investment destination and seeks to build a network connecting the global investment community with project promoters from both government and private sectors across India. Previously, Chandrima was a Director in the IDFC Group. She has over two decades of combined international and domestic experience in industry and in consulting, primarily at the public-private interface, with a focus on attracting private investment flows. She has also served on the boards of Uttarakhand Infrastructure Development Company Limited (U-Dec) and Delhi Integrated Multi Modal Transit System Ltd. (DIMTS).
G V Prasad is driven by a personal mission of creating high performing organizations which are sustainable through changing generations of products, people & technologies. His efforts have made Dr. Reddy’s, a place for talented individuals to reach their full potential.
He has transformed Dr. Reddy’s from a mid-sized domestic operation into a global integrated pharmaceutical company. Prasad’s emphasis on excellence has helped shape Dr. Reddy’s into an organization widely recognized for its scientific innovation, progressive people practices and high standards of corporate governance. A deep believer in sustainability, he spearheaded the company’s adoption of green technologies and processes. As a lover of nature and wildlife, Prasad is involved with the activities of the World Wildlife Fund, AP and Telangana chapter and other conservation minded organizations.
Mitesh Daga is Managing Director and member of the Indian leadership team at TPG Capital, the leading global private investment firm. Mitesh brings more than 18 years of investing, financial, entrepreneurial and operating experience from leading institutions. At TPG, Mitesh focuses on private equity with interest in healthcare, life sciences, consumer and technology. His deals at TPG include Manipal Hospitals, UPL, Sai Lifesciences and RR Kabel. Mitesh serves on the boards of Sai Lifesciences and RR Kabel.
Prior to joining TPG in 2014, he worked with Advent International in UK and subsequently in India where he was a part of the founding team and led healthcare investing. He also previously worked with Zephyr Peacock in India and CapitalOne in USA, and was co-founder of an emerging big data analytics business. Mr. Daga holds a degree in Chemical Engineering from the Indian Institute of Technology (IIT), Delhi, and is a CFA charter holder and a licensed pilot.
I have 10+ years of experience spanning academia and industry. At Intas (Biopharma Div.), as part of the senior leadership team, I have a multifaceted role ranging from R&D program strategy to commercial product life cycle management and global supply planning. As the head of business excellence and biopharma supply operations, I formulate and advise on biopharma strategy and operation. My team is responsible for strategizing the production and supply planning of 15 biosimilars for 'on-time' and 'right quantity' in domestic and global markets. We have successfully planned and launched Avastin and Prolia biosimilars in the domestic market and Neulasta biosimilar in the global market.
I started out as a B.tech in Industrial Biotechnology and then obtained a doctorate degree in molecular neuroscience from Univ. of Würzburg, Germany. I then completed post-doctoral research stint in Biophysics and Neuroscience from Univ. of California, San Francisco (UCSF). I have several peer authored publications including Journal of Neuroscience and Nature Neuroscience. Post my stint in EU and US, I returned to India and obtained a degree in business administration from the prestigious Indian School of Business, Hyderabad (ISB, Hyderabad). Post MBA, I joined Aurigene, a subsidiary of Dr. Reddy’s as a Global Business Development Manager and then shortly there after moved to Intas into the current role of Business Excellence and operations.
Currently working with Lupin Biotech, Pune as Head, Analytical R&D and CMC. Earlier worked with Dr. Reddy’s Biologics for about 12 years where played leadership roles in both in analytical R&D and product operations. I have PhD from Indian Institute of Science, Bangalore, Post- doctoral experience from UNC- Chapelhill, NC, USA. Overall 25+ years of experience in working with protein characterisation and associated method development and technologies
Co-founder Yapan Bio LLP, founder 2019
Vice-President (Head R&D) at CPL Biologicals (JV between Cadila Pharma and Novavax, USA) till April 2019
20 years of experience in advancing Vaccines, Biologics and Diagnostic from PoC to commercialization
Proven track record for innovations, process and method development, tech transfer, facility start-up
Experience of CRAMS management with international clients worth >10 m USD
Successfully developed multiple products for commercialization
Kaushik is the CEO of Healthspring, India’s largest provider of Corporate Health Solutions and Occupational Health services, with a presence across more than 90 locations in India, and India’s largest private primary care provider for individuals and families through its retail clinics and network.
Healthspring currently serves ~800,000 corporate and individual users, and ~200 companies. Healthspring is dedicated to bringing high-quality primary care to the country, and in so doing significantly improve medical outcomes and dramatically lower system costs. It is committed to growing on 4 pillars: quality of medical care, service excellence, dependability, and highest ethics.
Prior to founding Healthspring, Kaushik worked with management consulting firm Bain & Co. in Boston, Singapore and Delhi, for 11 years. At Bain, Kaushik worked extensively with hospitals, pharmaceuticals and med tech companies, as well as consumer and technology companies. He lead scale transformation projects with leading hospitals in the US and India.
Kaushik also worked extensively with Private Equity firms, and was responsible for leading Bain India’s Private Equity “ringfence”, a set of dedicated case teams.
He was one of the senior founders for Bain’s entry into India in 2006, and was responsible for heading up Bain India’s recruiting, and setting up people processes, in addition to case work.
Kaushik received a full scholarship for his undergraduate studies at Colby College, where he majored in Mathematics and Economics and graduated Magna cum Laude. He received his MBA from the Harvard Business School in 2003.
He is an active participant and speaker in Industry and Government forums on improving healthcare access in India, and is on the board of a non-profit delivering rural primary care as well as a Board Member for the Mumbai Government’s Civic and Social Amenities incubator (SMILE).
He was one of the Economic Times’ annual “40 under 40” business leaders for India in 2017 and one of CNBC India’s “Young Turks”.
Under his leadership, Healthspring has been recognized and awarded by numerous National and International bodies, including USAID (the only private Indian company to receive a debt guarantee from the US government), Frost & Sullivan, Healthcare Business International (best building of a Brand).
Kaushik is a Salzburg Global Fellow and a Fellow of the Royal Society of Medicine, UK.
A doctor by training and an entrepreneur by heart, Dr. Madhukar Gangadi, Founder and CEO of MedPlus Health Services Pvt. Ltd, is an exceptional blend of medical expertise and seasoned entrepreneurship. Under his strategic leadership, the company has established itself as a leading name in the pharmacy retail sector in India. With the philosophy of making high quality healthcare available for Indian consumers at a convenient cost, he continues his journey of innovation and growth..
Dr. Gangadi has an MBBS from Kurnool Medical College and an MBA from the Wharton School of Business.
He started his career with ICI in India in their businesses of Fibres & Speciality chemicals. Later, he rose to the position of General Manager with ICI / ZENECA in the U.K., overseeing their Asia Pacific and LatAm PTA operations for their Petrochemicals and Plastics division.
This was followed by a period as CEO at Roche Products Limited, after which he moved to Novartis in India in 1997, following the merger of Sandoz and Ciba-Geigy as CEO Healthcare.
Mr Shahani is former President, Swiss Indian Chamber of Commerce. He is President Emeritus of Organisation of Pharmaceuticals Producers of India (OPPI), is Past President of the Bombay Chamber of Commerce and Industry, and was on the Council of the International Federation of Pharmaceuticals Manufacturers Associations (IFPMA, Geneva). He is a thought leader in the Pharmaceutical Industry and has been actively involved in advocating for a strong Product Patent law in the country and Data Protection and liberalization of the price control mechanism for Pharmaceuticals. He has also strongly canvassed for deterrent legislation against counterfeit drugs and liberalisation of FDI in the Pharmaceutical Industry.